Researchers at the Weizmann Institute of Science in Israel investigated the relationships between different receptors in the cell.
The receptors - protein molecules on the cell's surface or within cells - take in biochemical messages secreted by other cells and pass them on into the cell's interior.
The scientists, led by Dr Mattia Lauriola, a postdoctoral fellow in the research group of Professor Yosef Yarden of the Weizmann Institute's Biological Regulation Department, working together with Professor Eytan Domany of the Physics of Complex Systems Department, focused on two particular receptors.
The second binds to a steroid hormone called a glucocorticoid (GC). Glucocorticoids play a role in maintaining the body's energy levels during the day, as well as the metabolic exchange of materials.
Also Read
It is often called the stress hormone because its levels rise in stressful situations, rapidly bringing the body to a state of full alert.
In the experiment, Lauriola and Yarden found that cell migration - the activity promoted by the EGF receptor - is suppressed when the GC receptor is bound to its steroid messenger.
Checking the levels of this activity in mice, they found that there was a significant difference: This receptor is much more active during sleep and quiescent during waking hours.
Researchers then decided to find out how relevant are these findings for cancers, particularly those which use the EGF receptors to grow and spread.
The scientists gave Lapatinib - one of the new generation of cancer drugs - to mouse models of cancer. This drug, used to treat breast cancer, is designed to inhibit EGFR, and thus to prevent the growth and migration of the cancer cells.
The experimental findings suggest that it is indeed the rise and fall in the levels of the GC steroids over the course of 24 hours that hinder or enable the growth of the cancer.
The conclusion, said scientists, is that it could be more efficient to administer certain anticancer drugs at night.